VS TR 2x Long VIX Futures ETF

ProShares Ultra VIX Short-Term Futures

MicroSectors Gold Miners 3X Leveraged ETN

Direxion Daily Gold Miners Bull 3X ETF

Direxion Daily Semicondct Bear 3X ETF

ProShares UltraPro Short QQQ

Direxion Technology Bear 3X Shares

VanEck Vectors Junior Gold Miners ETF

ProShares Ultra Silver

VanEck Vectors Gold Miners ETF

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

VS TR -1x Short VIX Futures ETF

Direxion Daily Gold Miners Bear 3X ETF

Direxion Daily Semicondct Bull 3X ETF

Bank Of Montreal MAX S&P 500 4X Leveraged ETNs due October 30

ProShares UltraPro QQQ

Direxion Daily Technology Bull 3X ETF

ProShares UltraShort Silver

AXS 2X Innovation ETF

ProShares UltraShort Bloomberg Natrl Gas

Imunon Inc. Common Stock

Oklo Inc.

NuScale Power Corporation Class A Common Stock

ASP Isotopes Inc. Common Stock

Cameco Corporation Common Stock

SolarEdge Technologies Inc. Common Stock

Intuit Inc. Common Stock

CompoSecure Inc. Class A Common Stock

GameStop Corporation Common Stock

RE/MAX Holdings Inc. Class A Common Stock

Siyata Mobile Inc. Common Shares

MINISO Group Holding Limited American Depositary Shares each representing four Ordinary Shares

Navitas Semiconductor Corporation Common Stock

Trio Petroleum Corp. Common Stock

Workday Inc. Class A Common Stock

Copart Inc. (DE) Common Stock

Pony AI Inc. American Depositary Shares

Ross Stores Inc. Common Stock

MicroStrategy Incorporated Common Stock Class A

Cleveland-Cliffs Inc. Common Stock

Click here to get full coverage on Imunon Stock (IMNN) Rockets on Clinical Trial Results - TipRanks

Imunon Stock (IMNN) Rockets on Clinical Trial Results  TipRanks

Imunon Stock (IMNN) Rockets on Clinical Trial Results - TipRanks

Click here to get full coverage on DNA Immunotherapy Developer IMUNON Raises $9.75M to Advance Phase 3 Clinical Program - Stock Titan

DNA Immunotherapy Developer IMUNON Raises $9.75M to Advance Phase 3 Clinical Program  Stock Titan

DNA Immunotherapy Developer IMUNON Raises $9.75M to Advance Phase 3 Clinical Program - Stock Titan

Click here to get full coverage on IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation - GlobeNewswire

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation  GlobeNewswire

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation - GlobeNewswire

Click here to get full coverage on IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules | IMNN Stock News - GuruFocus

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules | IMNN Stock News  GuruFocus

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules | IMNN Stock News - GuruFocus

Click here to get full coverage on Phase 3 Biotech IMUNON Halts Public Offering Plans: What This Means for DNA Immunotherapy Pipeline - Stock Titan

Phase 3 Biotech IMUNON Halts Public Offering Plans: What This Means for DNA Immunotherapy Pipeline  Stock Titan

Phase 3 Biotech IMUNON Halts Public Offering Plans: What This Means for DNA Immunotherapy Pipeline - Stock Titan

Click here to get full coverage on Biotech Stock Surges To Close The Week After Major Announcement - The Globe and Mail

Biotech Stock Surges To Close The Week After Major Announcement  The Globe and Mail

Biotech Stock Surges To Close The Week After Major Announcement - The Globe and Mail

Click here to get full coverage on IMNN stock touches 52-week low at $0.46 amid market challenges - Investing.com

IMNN stock touches 52-week low at $0.46 amid market challenges  Investing.com

IMNN stock touches 52-week low at $0.46 amid market challenges - Investing.com

Click here to get full coverage on IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewswire

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules  GlobeNewswire

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewswire

Click here to get full coverage on OVATION-3 Trial of IMNN-001 Seeks to Confirm Feasibility of Targeting IL-12 to Boost Immune Responses in Ovarian Cancer - OncLive

OVATION-3 Trial of IMNN-001 Seeks to Confirm Feasibility of Targeting IL-12 to Boost Immune Responses in Ovarian Cancer  OncLive

OVATION-3 Trial of IMNN-001 Seeks to Confirm Feasibility of Targeting IL-12 to Boost Immune Responses in Ovarian Cancer - OncLive

Click here to get full coverage on Imunon Inc (IMNN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance

Imunon Inc (IMNN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges  Yahoo Finance

Imunon Inc (IMNN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance

Click here to get full coverage on Imunon announces data from Phase 2 OVATION 2 study on IMNN-001 - TipRanks

Imunon announces data from Phase 2 OVATION 2 study on IMNN-001  TipRanks

Imunon announces data from Phase 2 OVATION 2 study on IMNN-001 - TipRanks

Click here to get full coverage on IMNN Announces Promising Phase 2 Results for Ovarian Cancer Therapy | IMNN Stock News - GuruFocus

IMNN Announces Promising Phase 2 Results for Ovarian Cancer Therapy | IMNN Stock News  GuruFocus

IMNN Announces Promising Phase 2 Results for Ovarian Cancer Therapy | IMNN Stock News - GuruFocus

Click here to get full coverage on Breakthrough: New Ovarian Cancer Drug Extends Patient Survival by 13 Months in Groundbreaking Trial Results - Stock Titan

Breakthrough: New Ovarian Cancer Drug Extends Patient Survival by 13 Months in Groundbreaking Trial Results  Stock Titan

Breakthrough: New Ovarian Cancer Drug Extends Patient Survival by 13 Months in Groundbreaking Trial Results - Stock Titan

Click here to get full coverage on IMUNON Announces Withdrawal of Form S-1 Registration Statement - GlobeNewswire

IMUNON Announces Withdrawal of Form S-1 Registration Statement  GlobeNewswire

IMUNON Announces Withdrawal of Form S-1 Registration Statement - GlobeNewswire

Click here to get full coverage on Imunon (IMNN) Withdraws SEC Registration for Planned Public Offering | IMNN Stock News - GuruFocus

Imunon (IMNN) Withdraws SEC Registration for Planned Public Offering | IMNN Stock News  GuruFocus

Imunon (IMNN) Withdraws SEC Registration for Planned Public Offering | IMNN Stock News - GuruFocus

Click here to get full coverage on IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer | IMNN Stock - GuruFocus

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer | IMNN Stock  GuruFocus

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer | IMNN Stock - GuruFocus

Click here to get full coverage on IMUNON Announces First Site Initiated for Pivotal Phase 3 - GlobeNewswire

IMUNON Announces First Site Initiated for Pivotal Phase 3  GlobeNewswire

IMUNON Announces First Site Initiated for Pivotal Phase 3 - GlobeNewswire

Click here to get full coverage on Imunon (IMNN) Downgraded Amid Concerns Over Financing Dilution | IMNN Stock News - GuruFocus

Imunon (IMNN) Downgraded Amid Concerns Over Financing Dilution | IMNN Stock News  GuruFocus

Imunon (IMNN) Downgraded Amid Concerns Over Financing Dilution | IMNN Stock News - GuruFocus

Click here to get full coverage on IMNN Downgraded to Hold by D. Boral Capital Analyst Jason Kolber - GuruFocus

IMNN Downgraded to Hold by D. Boral Capital Analyst Jason Kolber  GuruFocus

IMNN Downgraded to Hold by D. Boral Capital Analyst Jason Kolber - GuruFocus

Click here to get full coverage on Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer - Curetoday

Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer  Curetoday

Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer - Curetoday

Click here to get full coverage on IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting - GlobeNewswire

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting  GlobeNewswire

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting - GlobeNewswire

Click here to get full coverage on IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology - GlobeNewswire

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology  GlobeNewswire

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology - GlobeNewswire

Click here to get full coverage on Big Gains For Imunon, Merus, And Douglas Elliman - Finimize

Big Gains For Imunon, Merus, And Douglas Elliman  Finimize

Big Gains For Imunon, Merus, And Douglas Elliman - Finimize

Click here to get full coverage on IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - GlobeNewswire

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer  GlobeNewswire

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - GlobeNewswire

Click here to get full coverage on IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update  GlobeNewswire

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

Click here to get full coverage on Imunon Reports Prolonged Survival in Study of Potential Ovarian Cancer Treatment; Shares Soar Pre-Bell - marketscreener.com

Imunon Reports Prolonged Survival in Study of Potential Ovarian Cancer Treatment; Shares Soar Pre-Bell  marketscreener.com

Imunon Reports Prolonged Survival in Study of Potential Ovarian Cancer Treatment; Shares Soar Pre-Bell - marketscreener.com

Click here to get full coverage on IMUNON Announces Six-Month Data Showing Durability of - GlobeNewswire

IMUNON Announces Six-Month Data Showing Durability of  GlobeNewswire

IMUNON Announces Six-Month Data Showing Durability of - GlobeNewswire

Click here to get full coverage on IMNN: First Site Activated for Phase 3 OVATION 3 Trial… - Yahoo Finance

IMNN: First Site Activated for Phase 3 OVATION 3 Trial…  Yahoo Finance

IMNN: First Site Activated for Phase 3 OVATION 3 Trial… - Yahoo Finance

Click here to get full coverage on IMUNON, Inc. Presents Promising Phase 1 Data for IMNN-101 Vaccine, Highlighting Durability and Advantages Over mRNA Platforms - Nasdaq

IMUNON, Inc. Presents Promising Phase 1 Data for IMNN-101 Vaccine, Highlighting Durability and Advantages Over mRNA Platforms  Nasdaq

IMUNON, Inc. Presents Promising Phase 1 Data for IMNN-101 Vaccine, Highlighting Durability and Advantages Over mRNA Platforms - Nasdaq

Click here to get full coverage on IMUNON Announces Withdrawal of Form S-1 Registration Statement | - GuruFocus

IMUNON Announces Withdrawal of Form S-1 Registration Statement |  GuruFocus

IMUNON Announces Withdrawal of Form S-1 Registration Statement | - GuruFocus

Click here to get full coverage on New DNA Vaccine Outperforms mRNA: 6-Month COVID Protection After Single Dose - Stock Titan

New DNA Vaccine Outperforms mRNA: 6-Month COVID Protection After Single Dose  Stock Titan

New DNA Vaccine Outperforms mRNA: 6-Month COVID Protection After Single Dose - Stock Titan

Click here to get full coverage on IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - Stock Titan

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer  Stock Titan

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - Stock Titan

Click here to get full coverage on Breakthrough Ovarian Cancer Treatment Shows 46-Month Survival as FDA Clears Phase 3 Trial - Stock Titan

Breakthrough Ovarian Cancer Treatment Shows 46-Month Survival as FDA Clears Phase 3 Trial  Stock Titan

Breakthrough Ovarian Cancer Treatment Shows 46-Month Survival as FDA Clears Phase 3 Trial - Stock Titan

Click here to get full coverage on Imunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial Challenges - Yahoo Finance

Imunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial Challenges  Yahoo Finance

Imunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial Challenges - Yahoo Finance

Click here to get full coverage on IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025 - GlobeNewswire

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025  GlobeNewswire

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025 - GlobeNewswire

Click here to get full coverage on IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study - GlobeNewswire

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study  GlobeNewswire

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study - GlobeNewswire

Click here to get full coverage on IMNN - Imunon Inc Latest Stock News & Market Updates - Stock Titan

IMNN - Imunon Inc Latest Stock News & Market Updates  Stock Titan

IMNN - Imunon Inc Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on Imunon Withdraws Registration Statement Impacting Strategy - TipRanks

Imunon Withdraws Registration Statement Impacting Strategy  TipRanks

Imunon Withdraws Registration Statement Impacting Strategy - TipRanks

Click here to get full coverage on IMUNON’s IMNN-101 Vaccine Shows Promising Results in Phase 1 Trial, Demonstrates Cross-Reactivity Against COVID Variants - Contagion Live

IMUNON’s IMNN-101 Vaccine Shows Promising Results in Phase 1 Trial, Demonstrates Cross-Reactivity Against COVID Variants  Contagion Live

IMUNON’s IMNN-101 Vaccine Shows Promising Results in Phase 1 Trial, Demonstrates Cross-Reactivity Against COVID Variants - Contagion Live

Click here to get full coverage on First Effective IL-12 Immunotherapy Shows Survival Benefits in Advanced Ovarian Cancer - ASCO 2025 Preview - Stock Titan

First Effective IL-12 Immunotherapy Shows Survival Benefits in Advanced Ovarian Cancer - ASCO 2025 Preview  Stock Titan

First Effective IL-12 Immunotherapy Shows Survival Benefits in Advanced Ovarian Cancer - ASCO 2025 Preview - Stock Titan

Click here to get full coverage on IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer - GlobeNewswire

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer  GlobeNewswire

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer - GlobeNewswire

Click here to get full coverage on Imunon (IMNN): Analyst Maintains Buy Rating with $29 Price Target | IMNN Stock News - GuruFocus

Imunon (IMNN): Analyst Maintains Buy Rating with $29 Price Target | IMNN Stock News  GuruFocus

Imunon (IMNN): Analyst Maintains Buy Rating with $29 Price Target | IMNN Stock News - GuruFocus

Click here to get full coverage on IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer - GlobeNewswire

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer  GlobeNewswire

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer - GlobeNewswire

Click here to get full coverage on IMNN Stock Update: D. Boral Capital Lowers Price Target for Imun - GuruFocus

IMNN Stock Update: D. Boral Capital Lowers Price Target for Imun  GuruFocus

IMNN Stock Update: D. Boral Capital Lowers Price Target for Imun - GuruFocus

Click here to get full coverage on Imunon withdraws public offering registration - Investing.com

Imunon withdraws public offering registration  Investing.com

Imunon withdraws public offering registration - Investing.com

Click here to get full coverage on IMNN-001 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer - OncLive

IMNN-001 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer  OncLive

IMNN-001 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer - OncLive

Click here to get full coverage on Imunon announces new data from Phase 1 trial of IMNN-101 - TipRanks

Imunon announces new data from Phase 1 trial of IMNN-101  TipRanks

Imunon announces new data from Phase 1 trial of IMNN-101 - TipRanks

Click here to get full coverage on Imunon (IMNN) Price Target Reduced Amid Financial Concerns | IMN - GuruFocus

Imunon (IMNN) Price Target Reduced Amid Financial Concerns | IMN  GuruFocus

Imunon (IMNN) Price Target Reduced Amid Financial Concerns | IMN - GuruFocus

Click here to get full coverage on IMNN Unveils Promising Phase 1 Data for COVID-19 Vaccine Candidate | IMNN Stock News - GuruFocus

IMNN Unveils Promising Phase 1 Data for COVID-19 Vaccine Candidate | IMNN Stock News  GuruFocus

IMNN Unveils Promising Phase 1 Data for COVID-19 Vaccine Candidate | IMNN Stock News - GuruFocus

Click here to get full coverage on IMUNON Announces New Immunogenicity Data from Phase 1 - GlobeNewswire

IMUNON Announces New Immunogenicity Data from Phase 1  GlobeNewswire

IMUNON Announces New Immunogenicity Data from Phase 1 - GlobeNewswire

Click here to get full coverage on Imunon, Inc. (NASDAQ:IMNN) Q1 2025 Earnings Call Transcript - Insider Monkey

Imunon, Inc. (NASDAQ:IMNN) Q1 2025 Earnings Call Transcript  Insider Monkey

Imunon, Inc. (NASDAQ:IMNN) Q1 2025 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer… - Yahoo Finance

IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer…  Yahoo Finance

IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer… - Yahoo Finance

Click here to get full coverage on IMUNON (IMNN) Advances Ovarian Cancer Treatment with Promising S - GuruFocus

IMUNON (IMNN) Advances Ovarian Cancer Treatment with Promising S  GuruFocus

IMUNON (IMNN) Advances Ovarian Cancer Treatment with Promising S - GuruFocus

Click here to get full coverage on IMNN Secures Operational Funding Until Late Q2 2025 | IMNN Stock News - GuruFocus

IMNN Secures Operational Funding Until Late Q2 2025 | IMNN Stock News  GuruFocus

Imunon Inc (IMNN)

Price Chart

Key Statistics

Technicals

About IMNN

Latest News

Imunon Stock (IMNN) Rockets on Clinical Trial Results - TipRanks

DNA Immunotherapy Developer IMUNON Raises $9.75M to Advance Phase 3 Clinical Program - Stock Titan

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation - GlobeNewswire

Advanced Charts

Top Gainers

Top Losers